Freienbach, July 21, 2021 — EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications, today announced the appointment of Göran Linder to its Board of Directors.
“As the representative of EffRx’s major shareholder, I actively promoted the turn-around that the company and its highly professional staff so successfully completed a few years back. EffRx is now a solid and profitable company with lots of inherent and exciting potential. By joining the Board, it is my ambition to facilitate further development of the business and to proactively materialize a more extended and ambitious company roadmap,” commented Göran Linder, Board Member.
Göran Linder joins existing Board Members, Dr. Jonas Ekblom, Chairman and Dr. Alcide Barberis. Mr. Linder has over 30 years of diversified sales, business development and management experience. He is a proven, dedicated leader and entrepreneur, with a successful track record to grow start-ups and to generate shareholder value, including in numerous Life Science exits and IPO’s.
Mr. Linder is currently CEO and Member of the Board at Midroc Invest AB, Midroc New Technology AB and Midroc Finans AB. The Midroc Group of Swedish venture capital companies targets groundbreaking technologies entailing new and more sustainable ways to produce energy, grow food, purify water, produce goods and cure diseases. Additionally, Mr. Linder serves as Chairman and Board Member at several IT, Life Science and Cleantech companies.
About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.
EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset.
EffRx’s go-to-market competence is proven by the development, launch and lucrative expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.